

**(Neo-)Adjuvante Immuntherapie beim nicht-kleinzelligen Lungenkarzinom  
(S. 8–10)**

*M. Möller, W. Schütte*

Literatur:

1. Krebs in Deutschland 2017/2018. 13. Ausgabe. Robert Koch-Institut (Hrsg) und die Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (Hrsg). Berlin, 2021
  2. Ru Zhao Y et al. NELSON lung cancer screening study. *Cancer Imaging* 2011;11 Spec No A:S79-84
  3. Douillard JY et al. Cisplatin and vinorelbine for completely resected non-small cell lung cancer. Subgroup analysis of the lung adjuvant cisplatin evaluation. *J Thorac Oncol* 2010; 5:220–8
  4. Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial; *Lancet* 2021; 298(10308): 134–457
  5. Felip E et al. Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIa NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study. European Lung Cancer Congress 2022, Abstract 800
  6. Forde P et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. *N Engl J Med* 2022; 386: 1973–85
- 

**NSCLC im Stadium III – State of the Art und Trends (s. 12–17)**

*M. Kimmich, H.-G. Kopp*

Literatur:

1. Krebs in Deutschland 2017/2018. Berlin: Robert Koch-Institut; 2021
2. Brierley JD et al. TNM classification of malignant tumours: John Wiley & Sons; 2017.
3. Lee PC et al. Risk factors for occult mediastinal metastases in clinical stage I non-small cell lung cancer. *Ann Thorac Surg* 2007; 84(1): 177–81
4. De Leyn P et al. European trends in preoperative and intraoperative nodal staging: ESTS guidelines. *J Thorac Oncol* 2007; 2(4): 357–61
5. Network NCC. NSCLC (Version 3.2022) [Available from: [https://www.nccn.org/professionals/physician\\_gls/pdf/nscl.pdf](https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf)]
6. Osaki T et al. Survival and prognostic factors of surgically resected T4 non-small cell lung cancer. *Ann Thorac Surg* 2003; 75(6): 1745–51

7. Port JL et al. Surgical resection for multifocal (T4) non-small cell lung cancer: is the T4 designation valid? *Ann Thorac Surg* 2007; 83(2): 397–400
8. Sobin LH et al. *TNM classification of malignant tumours*: John Wiley & Sons; 2011.
9. Albain KS et al. Concurrent cisplatin/etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. *J Clin Oncol* 1995; 13(8): 1880–92
10. Hui Z et al. Effect of Postoperative Radiotherapy for Patients With pIIIA-N2 Non-Small Cell Lung Cancer After Complete Resection and Adjuvant Chemotherapy: The Phase 3 PORT-C Randomized Clinical Trial. *JAMA Oncol* 2021; 7(8): 1178–85
11. Le Pechoux C et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non-small-cell lung cancer and proven mediastinal N2 involvement (Lung ART): an open-label, randomised, phase 3 trial. *Lancet Oncol* 2022; 23(1): 104–14
12. Douillard JY et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIa non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *Lancet Oncol* 2006; 7(9): 719–27
13. Eberhardt WE et al. Long-term Survival and Competing Risks of Death in the ESPATUE Randomized Phase-III Trial in Stage III NSCLC. In: IASLC, editor. *World Congress on Lung Cancer*; Vienna, 2022
14. Curran WJ et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst* 2011; 103(19): 1452–60
15. Furuse K et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. *J Clin Oncol* 1999; 17(9): 2692–9
16. O'Rourke N et al. Concurrent chemoradiotherapy in non-small cell lung cancer. *Cochrane Database of Systematic Reviews*. 2010(6)
17. Auperin A et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. *J Clin Oncol* 2010; 28(13): 2181–90
18. Spigel DR et al. Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. *J Clin Oncol* 2022; 40(12): 1301–11
19. Pignon JP et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. *J Clin Oncol* 2008; 26(21): 3552–9
20. Wu YL et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. *N Engl J Med* 2020.
21. Wakelee HA et al. IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIa non-small cell lung cancer (NSCLC). *Wolters Kluwer Health*; 2021
22. Felip E et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIa non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. *Lancet* 2021; 398(10308): 1344–57

23. Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. *The Lancet* 2014; 383(9928): 1561–71
  24. Chaft JE et al. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer. *Nature reviews Clinical Oncology* 2021; 18(9): 547–57
  25. Felip E et al. P2. 16-03 CheckMate 816: a phase 3 trial of neoadjuvant nivolumab plus ipilimumab or chemotherapy vs chemotherapy in early-stage NSCLC. *Journal of Thoracic Oncology* 2018; 13(10): S831–S2
  26. Spicer J et al. Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO)+ platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC). Wolters Kluwer Health; 2021
- 

## **ASCO 2022: Neues zur Therapie des metastasierten Mammakarzinoms (S. 21–30)**

*C. Jackisch*

### Literatur:

1. Chmura SJ et al. NRG-BR002: A phase IIR/III trial of standard of care systemic therapy with or without stereotactic body radiotherapy (SBRT) and/or surgical resection (SR) for newly oligometastatic breast cancer (NCT02364557). *J Clin Oncol* 2022; 40:(suppl 16, abstract 1007)
2. Modi S et al. Trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. *J Clin Oncol* 2022; 40:(suppl 16, abstract LBA 3)
3. Denkert C et al. Neue Therapiemöglichkeiten beim metastasierten HER2-low Mammakarzinom - Konsequenzen für die histopathologische Diagnostik. *Pathologe* 2022 accepted for publication
4. Hamilton EP et al. Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03. *J Clin Oncol* 2022; 40:(suppl 16, abstract 1000)
5. Krop I et al. Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC). *J Clin Oncol* 2022; 40:(suppl 16, abstract 1002)
6. Finn R et al. Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2–ABC): Analyses from PALOMA-2. *J Clin Oncol* 2022; 40:(suppl 16, LBA 1003)
7. Finn RS et al. Palbociclib and Letrozol in Advanced Breast Cancer. *N Engl J Med* 2016; 375: 1925–36

8. Kalinsky K et al. A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. *J Clin Oncol* 2022; 40:(suppl 16, LBA 1004)
  9. Rugo H et al. Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (Pts) with hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer. *J Clin Oncol* 2022; 40:(suppl 16, LBA 1000)
  10. Jones R et al. Fulvestrant plus capivasertib versus fulvestrant plus placebo after relapse or progression on an aromatase inhibitor in metastatic, estrogen receptor-positive breast cancer (FAKTION): Overall survival and updated progression-free survival data with enhanced biomarker analysis. *J Clin Oncol* 2022; 40:(suppl 16, abstract 1005)
  11. Jhaveri K et al. Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial. *J Clin Oncol* 2022; 40:(suppl 16, abstract 1028)
  12. Barida A et al. Sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study. *J Clin Oncol* 2022; 40:(suppl 16, abstract 1071).
- 

## Trends, Tumormerkmale und Überleben beim Nicht-Plattenepithelkarzinom des Penis (S. 31–35)

*M. Wenzel, S. Banek, A. Becker, L. Kluth, F. K. H. Chun*

### Literatur:

1. Hakenberg, OW et al. EAU Guidelines on Penile Cancer 2018
2. Christodoulidou M et al. Epidemiology of penile cancer. *Curr Probl Cancer* 2015; 39: 126–36
3. Schoffer O et al. Penile cancer - Incidence, mortality, and survival in Saxony, Germany. *Urol Oncol* 2019; 37: 295.e1–295.e8
4. Burt LM et al. Stage presentation, care patterns, and treatment outcomes for squamous cell carcinoma of the penis. *Int J Radiat Oncol Biol Phys* 2014; 88(1): 94-100
5. Mistretta FA et al. Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. *World J Urol* 2020; 38: 725–32
6. Thuret R et al. Competing-risks analysis in patients with T1 squamous cell carcinoma of the penis. *BJU Int* 2013; 111(4 Pt B): E174–9
7. Thuret R. et al. Conditional survival predictions after surgery for patients with penile carcinoma. *Cancer* 2011; 117: 3723–30

8. Thuret R. et al. A population-based analysis of the effect of marital status on overall and cancer-specific mortality in patients with squamous cell carcinoma of the penis. *Cancer Causes Control* 2013; 24: 71–9
9. Bechara GR et al. Penile primary melanoma: analysis of 6 patients treated at Brazilian National Cancer Institute in the last eight years. *Int Braz J Urol* 2013; 39: 823–31
10. Jabiles AG et al. Penile melanoma: a 20-Year analysis of six patients at the National Cancer Institute of Peru, Lima. *Ecancermedicalsecience* 2017; 11: 731
11. Moses KA et al. Non-squamous cell carcinoma of the penis: single-center, 15-year experience. *World J Urol* 2014; 32: 1347–53
12. Sanchez A et al. Primary genitourinary melanoma: Epidemiology and disease-specific survival in a large population-based cohort. *Urol Oncol* 2016; 34: 166.e7–14
13. Sánchez-Ortiz R et al. Melanoma of the penis, scrotum and male urethra: a 40-year single institution experience. *J Urol*, 2005; 173: 1958–65
14. Bhambhani H, Greenberg D, Parham M et al., A population-level analysis of nonsquamous penile cancer: The importance of histology. *Urol Oncol* 2020
15. Wenzel M et al. Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. *Cancer Causes Control* 2022; 33: 25–35
16. Wenzel M et al. Comparison Between Urothelial and Non Urothelial Urethral Cancer. *Front Oncol* 2021; 10: 629692
17. Deuker M et al. Upper Urinary Tract Tumors: Variant Histology Versus Urothelial Carcinoma. *Clin Genitourin Cancer* 2021; 19: 117–24
18. Deuker M et al. Micropapillary Versus Urothelial Carcinoma of the Urinary Bladder: Stage at Presentation and Efficacy of Chemotherapy Across All Stages-A SEER-based Study. *Eur Urol Focus* 2020: 1332–38
19. Nocera L et al. Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. *Eur Urol Focus* 2021: 182–90
20. Jabiles AG et al. Penile melanoma: a 20-Year analysis of six patients at the National Cancer Institute of Peru, Lima. *Ecancermedicalsecience* 2017; 11: 731
21. Moses KA et al. Non-squamous cell carcinoma of the penis: single-center, 15-year experience. *World J Urol* 2014; 32: 1347–53